These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

633 related articles for article (PubMed ID: 18632634)

  • 1. Cathepsin G enhances mammary tumor-induced osteolysis by generating soluble receptor activator of nuclear factor-kappaB ligand.
    Wilson TJ; Nannuru KC; Futakuchi M; Sadanandam A; Singh RK
    Cancer Res; 2008 Jul; 68(14):5803-11. PubMed ID: 18632634
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cathepsin G-mediated activation of pro-matrix metalloproteinase 9 at the tumor-bone interface promotes transforming growth factor-beta signaling and bone destruction.
    Wilson TJ; Nannuru KC; Singh RK
    Mol Cancer Res; 2009 Aug; 7(8):1224-33. PubMed ID: 19671689
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Receptor activator of NF-kappaB ligand induces the expression of carbonic anhydrase II, cathepsin K, and matrix metalloproteinase-9 in osteoclast precursor RAW264.7 cells.
    Fujisaki K; Tanabe N; Suzuki N; Kawato T; Takeichi O; Tsuzukibashi O; Makimura M; Ito K; Maeno M
    Life Sci; 2007 Mar; 80(14):1311-8. PubMed ID: 17306833
    [TBL] [Abstract][Full Text] [Related]  

  • 4. RANKL acts directly on RANK-expressing prostate tumor cells and mediates migration and expression of tumor metastasis genes.
    Armstrong AP; Miller RE; Jones JC; Zhang J; Keller ET; Dougall WC
    Prostate; 2008 Jan; 68(1):92-104. PubMed ID: 18008334
    [TBL] [Abstract][Full Text] [Related]  

  • 5. RANK ligand is a prerequisite for cancer-associated osteolytic lesions.
    Kitazawa S; Kitazawa R
    J Pathol; 2002 Oct; 198(2):228-36. PubMed ID: 12237883
    [TBL] [Abstract][Full Text] [Related]  

  • 6. DU145 human prostate cancer cells express functional receptor activator of NFkappaB: new insights in the prostate cancer bone metastasis process.
    Mori K; Le Goff B; Charrier C; Battaglia S; Heymann D; Rédini F
    Bone; 2007 Apr; 40(4):981-90. PubMed ID: 17196895
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Receptor activator of NF-kappaB ligand enhances breast cancer-induced osteolytic lesions through upregulation of extracellular matrix metalloproteinase inducer/CD147.
    Rucci N; Millimaggi D; Mari M; Del Fattore A; Bologna M; Teti A; Angelucci A; Dolo V
    Cancer Res; 2010 Aug; 70(15):6150-60. PubMed ID: 20631064
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The heat shock protein 90 inhibitor, 17-allylamino-17-demethoxygeldanamycin, enhances osteoclast formation and potentiates bone metastasis of a human breast cancer cell line.
    Price JT; Quinn JM; Sims NA; Vieusseux J; Waldeck K; Docherty SE; Myers D; Nakamura A; Waltham MC; Gillespie MT; Thompson EW
    Cancer Res; 2005 Jun; 65(11):4929-38. PubMed ID: 15930315
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A cathepsin K inhibitor reduces breast cancer induced osteolysis and skeletal tumor burden.
    Le Gall C; Bellahcène A; Bonnelye E; Gasser JA; Castronovo V; Green J; Zimmermann J; Clézardin P
    Cancer Res; 2007 Oct; 67(20):9894-902. PubMed ID: 17942921
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumor-derived interleukin-8 stimulates osteolysis independent of the receptor activator of nuclear factor-kappaB ligand pathway.
    Bendre MS; Margulies AG; Walser B; Akel NS; Bhattacharrya S; Skinner RA; Swain F; Ramani V; Mohammad KS; Wessner LL; Martinez A; Guise TA; Chirgwin JM; Gaddy D; Suva LJ
    Cancer Res; 2005 Dec; 65(23):11001-9. PubMed ID: 16322249
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Matrix metalloproteinase (MMP)-13 regulates mammary tumor-induced osteolysis by activating MMP9 and transforming growth factor-beta signaling at the tumor-bone interface.
    Nannuru KC; Futakuchi M; Varney ML; Vincent TM; Marcusson EG; Singh RK
    Cancer Res; 2010 May; 70(9):3494-504. PubMed ID: 20406980
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Osteoprotegerin overexpression by breast cancer cells enhances orthotopic and osseous tumor growth and contrasts with that delivered therapeutically.
    Fisher JL; Thomas-Mudge RJ; Elliott J; Hards DK; Sims NA; Slavin J; Martin TJ; Gillespie MT
    Cancer Res; 2006 Apr; 66(7):3620-8. PubMed ID: 16585187
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 1'-Acetoxychavicol acetate inhibits RANKL-induced osteoclastic differentiation of RAW 264.7 monocytic cells by suppressing nuclear factor-kappaB activation.
    Ichikawa H; Murakami A; Aggarwal BB
    Mol Cancer Res; 2006 Apr; 4(4):275-81. PubMed ID: 16603641
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cathepsin G recruits osteoclast precursors via proteolytic activation of protease-activated receptor-1.
    Wilson TJ; Nannuru KC; Singh RK
    Cancer Res; 2009 Apr; 69(7):3188-95. PubMed ID: 19293192
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Histochemical evidence of osteoclastic degradation of extracellular matrix in osteolytic metastasis originating from human lung small carcinoma (SBC-5) cells.
    Li M; Amizuka N; Takeuchi K; Freitas PH; Kawano Y; Hoshino M; Oda K; Nozawa-Inoue K; Maeda T
    Microsc Res Tech; 2006 Feb; 69(2):73-83. PubMed ID: 16456838
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nuclear factor-kappaB-dependent mechanisms in breast cancer cells regulate tumor burden and osteolysis in bone.
    Gordon AH; O'Keefe RJ; Schwarz EM; Rosier RN; Puzas JE
    Cancer Res; 2005 Apr; 65(8):3209-17. PubMed ID: 15833852
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Paclitaxel inhibits osteoclast formation and bone resorption via influencing mitotic cell cycle arrest and RANKL-induced activation of NF-κB and ERK.
    Ang ES; Pavlos NJ; Chim SM; Feng HT; Scaife RM; Steer JH; Zheng MH; Xu J
    J Cell Biochem; 2012 Mar; 113(3):946-55. PubMed ID: 22034016
    [TBL] [Abstract][Full Text] [Related]  

  • 18. RANKL signaling in bone physiology and cancer.
    Dougall WC
    Curr Opin Support Palliat Care; 2007 Dec; 1(4):317-22. PubMed ID: 18685382
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-tumor effect in human breast cancer by TAE226, a dual inhibitor for FAK and IGF-IR in vitro and in vivo.
    Kurio N; Shimo T; Fukazawa T; Takaoka M; Okui T; Hassan NM; Honami T; Hatakeyama S; Ikeda M; Naomoto Y; Sasaki A
    Exp Cell Res; 2011 May; 317(8):1134-46. PubMed ID: 21338601
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The RANK/RANKL/OPG triad in cancer-induced bone diseases.
    Dougall WC; Chaisson M
    Cancer Metastasis Rev; 2006 Dec; 25(4):541-9. PubMed ID: 17180711
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.